RxDoctor Payments Data

Douglas Gleaton, MD

Family Medicine · Charleston, SCNPI 1124226006

Payments from drug & device makers

$2,618in general payments, 2019–2025

Across 109 payments — averaging $24.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$626
  • Lilly USA, LLC$418
  • AstraZeneca$383
  • Novo Nordisk$205
  • Abbott$190
  • Bayer$188
  • plus $608 from 13 others

What the payments were for

  • Food & beverage$2,613100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,618 in reported general payments places this provider in the 75th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$197,385
Medicare patients
447
Services billed
4,273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin115$139,858
EliquisApixaban121$135,271
MounjaroTirzepatide112$128,629
OzempicSemaglutide93$108,386
JanuviaSitagliptin Phosphate81$70,492
FarxigaDapagliflozin Propanediol62$55,198
XareltoRivaroxaban49$51,243
Tresiba Flextouch U-200Insulin Degludec55$51,207
Janumet XrSitagliptin Phos/Metformin Hcl37$39,111
TrulicityDulaglutide25$34,709
EntrestoSacubitril/Valsartan31$29,161
RybelsusSemaglutide18$27,368
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog26$27,259
TradjentaLinagliptin23$22,465
InvokanaCanagliflozin18$16,672

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$38$174,576151 claims
Lilly USA, LLCMounjaro, Trulicity$418$163,338137 claims
Novo NordiskOzempic, Rybelsus$205$135,754111 claims
PfizerEliquis$37$135,271121 claims
MerckJanuvia, Janumet Xr, Belsomra$107$115,037129 claims
Johnson & JohnsonXarelto, Invokana$626$67,91567 claims
AstraZenecaFarxiga, Symbicort$383$59,52882 claims
NovartisEntresto$66$29,16131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →